Financial Performance - The company's operating revenue for Q1 2024 was ¥72,402,604.63, representing a year-on-year increase of 33.19%[5] - Net profit attributable to shareholders was ¥12,771,702.45, reflecting a significant increase of 207.30% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥12,856,353.88, which is up by 213.43% year-on-year[5] - Basic and diluted earnings per share both stood at ¥0.16, marking an increase of 128.57%[6] - Net profit for Q1 2024 was ¥12,771,727.42, representing a significant increase of 207.5% compared to ¥4,156,112.07 in Q1 2023[20] - The company reported a profit before tax of ¥14,943,261.17, compared to ¥4,157,012.21 in the same period last year, marking a substantial increase[20] - The total comprehensive income for Q1 2024 was ¥12,771,727.42, significantly higher than ¥4,156,112.07 in Q1 2023[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,211,045,221.04, showing a decrease of 1.58% from the end of the previous year[6] - The company's total assets amounted to ¥1,211,045,221.04, slightly down from ¥1,230,461,176.67 in the previous year[16] - Total liabilities decreased to ¥170,604,697.04 from ¥203,192,380.09, indicating a reduction of 16.0%[16] - The equity attributable to shareholders increased to ¥1,040,040,499.03 from ¥1,027,268,796.58, reflecting a growth of 1.2%[16] Cash Flow - The net cash flow from operating activities was negative at -¥3,243,303.78, with no applicable year-on-year comparison[5] - Net cash flow from operating activities for Q1 2024 was -CNY 3,243,303.78, an improvement from -CNY 4,827,777.10 in Q1 2023[22] - Cash inflow from operating activities totaled CNY 30,066,938.87 in Q1 2024, compared to CNY 35,297,110.99 in Q1 2023, showing a decline of 14.73%[21] - Cash outflow from operating activities was CNY 33,310,242.65 in Q1 2024, down from CNY 40,124,888.09 in Q1 2023, indicating a 17.2% reduction[22] - The company's cash and cash equivalents as of March 31, 2024, amount to ¥30,217,615.92, down from ¥36,379,845.35 as of December 31, 2023[14] - The ending cash and cash equivalents balance for Q1 2024 was CNY 30,217,615.90, down from CNY 729,733,456.41 in Q1 2023[22] Shareholder Information - The company reported a total of 10,000 ordinary shareholders as of the end of the reporting period[9] - Total number of common shareholders at the end of the reporting period is 9,513[10] - The largest shareholder, Han Jianglong, holds 11,241,799 shares, representing 13.93% of the total shares[10] - The second largest shareholder, Lianyungang Deyufeng Investment Partnership, holds 10,308,091 shares, representing 12.77%[10] Research and Development - Research and development expenses totaled ¥5,392,889.91, accounting for 7.45% of operating revenue, a decrease of 1.55 percentage points[6] - Research and development expenses for Q1 2024 were ¥5,392,889.91, up 10.3% from ¥4,890,995.61 in Q1 2023[19] - The company has not reported any new product or technology developments in the current quarter[12] Mergers and Acquisitions - There are no significant mergers or acquisitions reported during the period[12] - The company did not report any net profit from merged entities in the current or previous periods[21] Future Guidance - The company has not provided specific future guidance or market expansion strategies in the current report[12] - The company is not applying new accounting standards for the current reporting period[23]
华海诚科(688535) - 2024 Q1 - 季度财报